Lonza participated in the gene therapy developer's series A round alongside Partners Innovation Fund, having also licensed technology to the startup.
US-based gene therapy developer Affinia Therapeutics completed a $60m series A round on Tuesday featuring biotechnology and chemicals producer Lonza Group and care provider Partners Healthcare’s Partners Innovation Fund.
The round was co-led by F-Prime Capital, a subsidiary of investment and financial services group Fidelity, and venture capital firm New Enterprise Associates, and included Atlas Venture and Alexandria Venture Investments, the VC arm of real estate investment trust Alexandria Real Estate Equities.
Affinia is developing gene therapies for use in…
